Vijaya Diagnostic Centre has announced a final dividend of ₹2 per equity share for the financial year ending March 31, 2026. This represents a 200% dividend on the face value of ₹1 per share, pending approval from shareholders at the upcoming Annual General Meeting (AGM). The dividend will be credited or dispatched within specified timelines following the AGM, with the AGM date and record date for dividend payment to be announced later.
In addition to the dividend declaration, Vijaya Diagnostic’s Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board also noted the decision of Dr. D Nageshwar Reddy not to seek re-appointment as an Independent Director for a second term due to pre-occupations and other professional commitments. His current term will conclude on May 25, 2026.
The board further approved the re-appointment of M/s. Santhosh & Associates as the Cost Auditors for the financial year 2026-27. The firm brings extensive experience in cost audits, compliance, and consultancy services.
Moreover, the board granted 1,79,500 Employee Stock Options (ESOPs) under the ‘VDCL Employee Stock Option Plan 2018’. These options are convertible into equity shares of ₹1 each and are priced at ₹784 per option, reflecting a 20% discount on the average closing price over the preceding three months.
Finally, Vijaya Diagnostic will acquire MRI, EEG, and NCV Services Business from Medinova Millennium MRI Services LLP, a wholly-owned subsidiary.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).